Fatigue in men with castration resistant prostate cancer treated with enzalutamide

Share :
Published: 21 Oct 2016
Views: 2639
Dr Simon Chowdhury - Guy's Hospital, London, UK

Dr Chowdhury speaks with ecancertv at ESMO 2016 about the effects of enzalutamide, an androgen-receptor antagonist, on men with prostate cancer that has not responded to testosterone-lowering.

Focusing on the side effects of four trials, he describes how the low incidence of fatigue is a comparably minor risk, considering the overall benefits of enzalutamide therapy.

Dr Chowdhury also spoke with ecancer about cancer registries here.